These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29393241)

  • 1. The Heterogeneity of Prostate Cancer: A Practical Approach.
    Tolkach Y; Kristiansen G
    Pathobiology; 2018; 85(1-2):108-116. PubMed ID: 29393241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
    Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
    Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.
    Brocks D; Assenov Y; Minner S; Bogatyrova O; Simon R; Koop C; Oakes C; Zucknick M; Lipka DB; Weischenfeldt J; Feuerbach L; Cowper-Sal Lari R; Lupien M; Brors B; Korbel J; Schlomm T; Tanay A; Sauter G; Gerhäuser C; Plass C;
    Cell Rep; 2014 Aug; 8(3):798-806. PubMed ID: 25066126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity and genetic characteristics of prostate cancer.
    Wu B; Lu X; Shen H; Yuan X; Wang X; Yin N; Sun L; Shen P; Hu C; Jiang H; Wang D
    Int J Cancer; 2020 Jun; 146(12):3369-3378. PubMed ID: 32159858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial genomic heterogeneity within localized, multifocal prostate cancer.
    Boutros PC; Fraser M; Harding NJ; de Borja R; Trudel D; Lalonde E; Meng A; Hennings-Yeomans PH; McPherson A; Sabelnykova VY; Zia A; Fox NS; Livingstone J; Shiah YJ; Wang J; Beck TA; Have CL; Chong T; Sam M; Johns J; Timms L; Buchner N; Wong A; Watson JD; Simmons TT; P'ng C; Zafarana G; Nguyen F; Luo X; Chu KC; Prokopec SD; Sykes J; Dal Pra A; Berlin A; Brown A; Chan-Seng-Yue MA; Yousif F; Denroche RE; Chong LC; Chen GM; Jung E; Fung C; Starmans MH; Chen H; Govind SK; Hawley J; D'Costa A; Pintilie M; Waggott D; Hach F; Lambin P; Muthuswamy LB; Cooper C; Eeles R; Neal D; Tetu B; Sahinalp C; Stein LD; Fleshner N; Shah SP; Collins CC; Hudson TJ; McPherson JD; van der Kwast T; Bristow RG
    Nat Genet; 2015 Jul; 47(7):736-45. PubMed ID: 26005866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathology of Prostate Cancer.
    Kulac I; Roudier MP; Haffner MC
    Clin Lab Med; 2024 Jun; 44(2):161-180. PubMed ID: 38821639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A concise update on prostate pathology.
    Xu W; Zhou M
    Cesk Patol; 2014; 50(4):120-8. PubMed ID: 25418898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and phenotypic heterogeneity in prostate cancer.
    Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
    Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
    Roy-Burman P; Zheng J; Miller GJ
    Mol Med Today; 1997 Nov; 3(11):476-82. PubMed ID: 9430782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal origin and spread of metastatic prostate cancer.
    Van Etten JL; Dehm SM
    Endocr Relat Cancer; 2016 Apr; 23(4):R207-17. PubMed ID: 27000662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental challenges to modeling prostate cancer heterogeneity.
    Flores-Téllez TDNJ; Baena E
    Cancer Lett; 2022 Jan; 524():194-205. PubMed ID: 34688843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-assisted three-dimensional analysis of multifocal/multicentric prostate cancer.
    Fujii T; Ishida E; Shimada K; Hirao K; Tanaka N; Fujimoto K; Konishi N
    Cancer Invest; 2014 Aug; 32(7):303-10. PubMed ID: 24827595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized Prostate Cancer Is Spatially and Genomically Heterogeneous.
    Cancer Discov; 2015 Jul; 5(7):691. PubMed ID: 26045016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Shah RB; Chinnaiyan AM
    Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones: mechanisms and consequences.
    Ben Jemaa A; Bouraoui Y; Oueslati R
    Histol Histopathol; 2014 Oct; 29(10):1263-80. PubMed ID: 24788382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA expression is highly homogenous in primary prostate cancer.
    Tsourlakis MC; Klein F; Kluth M; Quaas A; Graefen M; Haese A; Simon R; Sauter G; Schlomm T; Minner S
    Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):449-55. PubMed ID: 26153794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.